Kamell Eckroth-Bernard, MD
Vascular Surgery · Fresno, CANPI 1558522094
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Shockwave Medical, Inc at 41.4% of the total. Reporting peaked in 2024 at $8,974 and has fallen 93.2% since, to $607 in 2025.
Across 145 payments — averaging $123.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$7K
- W. L. Gore & Associates, Inc.$4K
- Silk Road Medical, Inc.$2K
- Abbott$1K
- Medtronic$847
- Penumbra, Inc.$299
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$6,60037%
- Travel & lodging$4,09623%
- Food & beverage$7,11540%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 12 | $7,386 |
| W. L. Gore & Associates, Inc. | 43 | $4,431 |
| Silk Road Medical, Inc. | 21 | $2,341 |
| Abbott | 12 | $1,078 |
| Medtronic(2 entities) | 15 | $847 |
| Penumbra, Inc. | 2 | $299 |
| Bolton Medical Inc | 7 | $251 |
| Cook Medical LLC | 4 | $246 |
| Boston Scientific | 3 | $169 |
| Stryker | 1 | $138 |
| E.r. Squibb & Sons, L.L.C. | 7 | $136 |
| Elutia, Inc. | 4 | $106 |
| Endologix LLC | 1 | $94 |
| Artivion, Inc. | 2 | $89 |
| Lemaitre Vascular, Inc. | 3 | $79 |
| Johnson & Johnson | 2 | $49 |
| AstraZeneca | 2 | $38 |
| Inari Medical, Inc. | 1 | $25 |
| Cordis US CORP. | 1 | $20 |
| Livanova USA, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$7,185
- ENROUTE Transcarotid Neuroprotection System$2,440
- ENHANCE Transcarotid Peripheral Access Kit$1,320
- ENROUTE Transcarotid Stent System$1,186
- ENROUTE 0.014 Guidewire$1,186
- VIABAHN Endoprosthesis$1,074
- ENROUTE Transcarotid Stent$825
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$742
- OMNILINK ELITE$679
- EXCLUDER Iliac Branch Endoprosthesis$494
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$429
- Endurant$295
- VIABAHN VBX Balloon Expandable Endoprosthesis$192
- RUBY Coil$166
- VIABAHN Endoprosthesis with Heparin Bioactive Surface$165
- EXCLUDER AAA Endoprosthesis$161
- Grafts$154
- ARTIX MT$138
- Indigo System$133
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$125
How this compares
$17,852 in reported general payments places this provider in the 80th percentile of 519 vascular surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 45 | $35,826 |
| ClopidogrelClopidogrel Bisulfate | 88 | $1,193 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $168 |
| Atorvastatin Calcium | 11 | $160 |
| Simvastatin | 14 | $39 |
| Alprazolam | 15 | $15 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $49 | $35,82645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 519 vascular surgery providers in California.
Other vascular surgery in Fresno
- Leigh Ann ObanionFresno$469K
- Randall SternFresno$70K
- Son DuongFountain Valley$503K
- Venita ChandraPalo Alto$488K
- Sukgu HanLos Angeles$477K
- Trevor DerderianRancho Mirage$359K
- Karthikeshwar KasirajanPalo Alto$349K
- Johnathon RolloLos Angeles$337K
- Melissa LojaFairfield$272K
- Jason LeePalo Alto$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.